Axitare

Axitare is a preclinical-stage biotechnology company focused on the discovery and development of small molecule therapeutics for neurodegenerative diseases. The company's core technology centers on preventing the misfolding and aggregation of key proteins, such as alpha-synuclein and tau, which are implicated in the progression of Parkinson's and Alzheimer's diseases. Spun out from the University of Pennsylvania, Axitare utilizes proprietary screening and design platforms to identify compounds that stabilize native protein conformations. Their mission is to deliver disease-modifying therapies that halt or reverse the neurodegenerative process. The company leverages the expertise of its founders in protein chemistry and neurobiology to target the root causes of proteinopathies.